Wilex reduced to contract research as Rencarex fails to inspire any interest
This article was originally published in Scrip
Executive Summary
Wilex is reducing its employees by 80% and focusing its business on contract research and the ADC technology at its subsidiary Heidelberg Pharma following a failure "to obtain project funding and licensing partnerships," it said.